iSchemaView announced this week it has received FDA clearance for RAPID CTA, the most recent addition to the company’s neuroimaging platform.
RAPID CTA was designed to help with the interpretation of CT angiography (CTA) exams, producing clear CTA maps in a matter of minutes. These maps assist specialists with patient triage, clinical decision making and more.
“Our goal is to provide healthcare professionals around the world with the most comprehensive and intuitive suite of imaging solutions possible,” Don Listwin, CEO of iSchemaView, said in a prepared statement. “With new FDA clearance and the release of RAPID CTA, we are making good on that goal. We ensure physicians can take advantage of RAPID’s power whether they choose plain CT, CT angiography, CT perfusion or MR diffusion and perfusion. It’s all about offering them the right imaging solution choice, for the right patient at the right time.”
“The new automated RAPID CTA tool makes it easy for community hospitals to quickly identify potential candidates for treatment and for experts at the comprehensive centers to verify that the patient is appropriate for transfer,” Greg Albers, co-founder of iSchemaView and a professor of neurology at Stanford University, said in the same statement.